ArunA has conducted multiple pre-clinical studies of our lead product, AB126, in multiple in vivo models of stroke demonstrating the power of exosomes to modify disease.
These studies have shown that our exosomes enhance the nervous system’s self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size and improved mobility.
To date, our proprietary native exosomes have demonstrated:
Proof-of-concept in large and small preclinical models
The capability to reduce inflammation and enhance neural function
Capability of crossing the blood brain barrier non-invasively and reach the site of injury
Ability to administer to multiple intravenous (IV) dosing without adverse response
Reduced hemorrhaging within 24 hours post injury